Requests may be approved when ANY one of the following indication-specific groups is met
Age under 19: Individual is under 19 years of age
Breast cancer - single agent after prior combo chemo: Individual has a diagnosis of breast cancer AND is using Abraxane as a single agent after failure on combination chemotherapy for metastatic disease or relapsed within 6 months of adjuvant therapy (Label) AND individual has had previous chemotherapy including an anthracycline unless clinically contraindicated
Breast cancer - recurrent unresectable or metastatic HER2-negative: Individual has recurrent unresectable or metastatic (stage IV) HER2-negative breast cancer AND is using Abraxane as a single agent or in combination with carboplatin AND disease is hormone receptor–positive and refractory to endocrine therapy or presents with visceral crisis
(NCCN 2A)
Breast cancer - triple negative high burden: Individual has triple-negative breast cancer with high tumor burden, rapidly progressing disease, or visceral crisis AND is using Abraxane as a single agent or in combination with carboplatin AND use is either first-line if PD-L1 < 10 and no germline BRCA1/2 mutation (NCCN 1) OR second-line and beyond
(NCCN 2A)
Breast cancer - PD-L1 positive TNBC with pembrolizumab: Individual has PD-L1–positive triple-negative breast cancer AND is using Abraxane in combination with pembrolizumab AND use is either first-line therapy (NCCN 1) OR second and subsequent lines if a PD‑1/PD‑L1 inhibitor has not previously been used (NCCN 2A)
Breast cancer - HER2 positive fourth-line+: Individual has HER2‑positive breast cancer AND is using Abraxane as fourth‑line therapy and beyond in combination with trastuzumab (or trastuzumab biosimilar)
(NCCN 2A)
Taxane hypersensitivity - breast/solid tumors: Treatment of any breast cancer or other solid tumor when taxane therapy is appropriate and the individual has confirmed hypersensitivity to solvent‑based paclitaxel or docetaxel (NCCN 2A)
Cervical cancer - recurrent/metastatic: Individual has recurrent unresectable or metastatic cervical cancer AND is using Abraxane as second‑line or subsequent therapy AND as a single agent
(NCCN 2A)
Melanoma (cutaneous): Individual has metastatic or unresectable cutaneous melanoma AND is using Abraxane as a single agent or in combination with carboplatin AND as second‑line or subsequent therapy AND has ECOG performance status 0‑2ECOG 0-2
(NCCN 2A)
Uveal melanoma: Individual has unresectable or metastatic uveal melanoma AND is using Abraxane as single‑agent therapy
(NCCN 2A)
Kaposi sarcoma: Individual has Kaposi sarcoma AND is paclitaxel intolerant AND has relapsed/refractory advanced disease AND is using Abraxane as subsequent systemic therapy and as a single agent OR is using Abraxane for KICS in combination with rituximab (or biosimilar)
(NCCN 2A)
NSCLC - single agent for first progression: Individual has recurrent, advanced, or metastatic NSCLC AND is using Abraxane as a single agent for first progression after initial systemic therapy (if not already given) AND has ECOG performance status 0‑2ECOG 0-2
(NCCN 2A)
NSCLC - squamous first-line with pembrolizumab and carboplatin: Individual has recurrent, advanced, or metastatic squamous NSCLC AND is using Abraxane as first‑line therapy in combination with pembrolizumab and carboplatin AND has ECOG performance status 0‑2ECOG 0-2
(NCCN 1, 2A)
NSCLC - nonsquamous first-line with atezolizumab and carboplatin: Individual has recurrent, advanced, or metastatic nonsquamous NSCLC AND is using Abraxane as first‑line therapy in combination with atezolizumab and carboplatin AND has ECOG performance status 0‑2ECOG 0-2
(NCCN 2A)
NSCLC - subsequent after targeted therapy: Individual has recurrent, advanced, or metastatic nonsquamous NSCLC AND is using Abraxane as subsequent therapy after failure of a kinase inhibitor targeted agent AND is using in combination with carboplatin and atezolizumab AND has ECOG performance status 0‑2ECOG 0-2
(NCCN 1, 2A)
NSCLC - tremelimumab/durvalumab regimen: Individual has recurrent, advanced, or metastatic squamous NSCLC AND is using Abraxane as first‑line therapy with tremelimumab‑actl, durvalumab, and carboplatin AND has PD‑L1 expression ≥ 1% and ≤ 49% AND is not receiving systemic immunosuppressant therapy AND has ECOG performance status 0‑2PD‑L1 1-49%; ECOG 0-2
(NCCN 2A)
Ovarian cancer: Individual has epithelial ovarian, fallopian tube, or primary peritoneal cancer AND is using Abraxane as a single agent for persistent or recurrent disease OR with carboplatin if taxane hypersensitivity OR in combination with Lifyorli (relacorilant) for platinum‑resistant disease in those who have received 1–3 prior systemic regimens with at least one including bevacizumab
(NCCN 1, 2A; FDA addition per document history)
Pancreatic adenocarcinoma: Individual has metastatic adenocarcinoma of the pancreas AND is using Abraxane in combination with gemcitabine
(Label, NCCN 1, 2A)
Locally advanced pancreatic disease: Individual has locally advanced adenocarcinoma of the pancreas AND is using Abraxane in combination with gemcitabine as first‑line, subsequent, or continuation therapy
(NCCN 2A)
Endometrial carcinoma: Individual has endometrial carcinoma AND is using Abraxane as second‑line or subsequent therapy AND as a single agent
(NCCN 2A)
Vaginal cancer: Individual has locally advanced recurrent or metastatic vaginal cancer AND is using Abraxane as second‑line or subsequent therapy AND as a single agent
(NCCN 2A)
Small bowel adenocarcinoma: Individual has advanced or metastatic small bowel adenocarcinoma AND is using Abraxane as a single agent or in combination with gemcitabine as initial or subsequent therapy
(NCCN 2A)
Ampullary adenocarcinoma: Individual has ampullary adenocarcinoma (pancreatobiliary or mixed type) AND is using Abraxane in combination with gemcitabine AND has ECOG performance status 0‑2ECOG 0-2
(NCCN 2A)
Biliary tract cancer: Individual has biliary tract cancer AND is using Abraxane in combination with gemcitabine for unresectable disease, resected gross residual disease, or metastatic disease AND disease does not present with jaundice
(NCCN 2A)
Solid tumors with taxane hypersensitivity: Individual has a solid tumor for which taxane therapy is medically appropriate and has confirmed hypersensitivity to solvent‑based paclitaxel or docetaxel (NCCN 2A)